Description: Developing next generation kinase inhibitors for autoimmune disease & cancer.*Molecular structure of TYK2 kinase (blue) and a prototype inhibitor (gold) About us > https://sareum.com/wp-content/uploads/2023/03/3NYX_camera-spin-2.mp4 SCROLL DOWN Welcome to Sareum.Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.We recognise the crucial role of the TYK/JAK
SCROLL DOWN
Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.
We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.